Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Inter RAO reported for 2022 according to RAS

3/6/23 IRAO

Moscow Exchange's Supervisory Board will discuss tomorrow the AGM's recommendation on dividends for 2022

3/6/23 MOEX

Positive Technologies disclosed management metrics and gave a dividend benchmark

3/6/23 POSI

Perekryostok Vprok began to cooperate with Yandex.Food and Delivery Club

3/6/23 FIVE

Yandex's Russian business may go under management

3/6/23 YNDX

MTS wants to buy the ticket operator TicketsCloud

3/6/23 MTSS

Abrau-Durso sold its champagne house in France

3/6/23 ABRD

Novotek is ready to buy 27.5% in the Sakhalin-2 project

3/6/23 NVTK

Rusagro's profit in 2022 decreased sixfold

3/6/23 RAGR

Sistema refused to buy 47.7% of Melon Fashion Group

3/6/23 AFKS